Coherus BioSciences Inc
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin… Read more
Coherus BioSciences Inc (CHRS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.323x
Based on the latest financial reports, Coherus BioSciences Inc (CHRS) has a cash flow conversion efficiency ratio of -0.323x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.72 Million) by net assets ($61.01 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Coherus BioSciences Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Coherus BioSciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Coherus BioSciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Coherus BioSciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
China Travel International Investment Hong Kong Limited
F:CTI
|
0.015x |
|
Zhejiang Talent Television&Film Co Ltd
SHE:300426
|
-0.598x |
|
Odfjell S.E. Series B
LSE:0J78
|
N/A |
|
Everyday Network
SHE:300295
|
0.071x |
|
South Dakota Soybean Processors LLC
PINK:SDSYA
|
0.061x |
|
Kung Long Batteries Industrial Co Ltd
TW:1537
|
0.106x |
|
NEOWIZ
KQ:095660
|
0.074x |
|
Yaari Digital Integrated Services Limited
NSE:YAARI
|
0.000x |
Annual Cash Flow Conversion Efficiency for Coherus BioSciences Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Coherus BioSciences Inc from 2012 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $61.01 Million | $-138.51 Million | -2.270x | -1565.96% |
| 2024-12-31 | $-131.99 Million | $-20.44 Million | 0.155x | -82.87% |
| 2023-12-31 | $-193.43 Million | $-174.88 Million | 0.904x | -48.47% |
| 2022-12-31 | $-137.42 Million | $-241.12 Million | 1.755x | +558.10% |
| 2021-12-31 | $97.73 Million | $-37.43 Million | -0.383x | -169.82% |
| 2020-12-31 | $280.97 Million | $154.15 Million | 0.549x | +103.57% |
| 2019-12-31 | $105.21 Million | $28.36 Million | 0.269x | -93.47% |
| 2018-12-31 | $-38.59 Million | $-159.27 Million | 4.127x | +162.92% |
| 2017-12-31 | $30.54 Million | $-200.29 Million | -6.559x | +49.73% |
| 2016-12-31 | $19.35 Million | $-252.54 Million | -13.049x | -183.72% |
| 2015-12-31 | $-6.93 Million | $-107.99 Million | 15.585x | +4448.32% |
| 2014-12-31 | $66.76 Million | $-23.93 Million | -0.358x | +1.51% |
| 2013-12-31 | $-42.38 Million | $15.42 Million | -0.364x | +81.67% |
| 2012-12-31 | $9.19 Million | $-18.25 Million | -1.986x | -- |